Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2025 | Drug-drug interaction management with the novel anti-CMV agents letermovir and maribavir

In this interview, Per Ljungman, MD, PhD, Karolinska Institutet, Stockholm, Sweden, comments on the importance of taking into consideration drug-drug interactions when administering the novel anti-cytomegalovirus (CMV) agents letermovir and maribavir. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

As with all drugs, interactions are important in our patients because our patients have many different pharmaceutical agents on board at the same time. These two drugs are slightly different. Letermovir has more interactions than maribavir, but usually with drugs that we monitor anyway, where we’re used to checking concentration by therapeutic drug monitoring, such as the immunosuppressive agents and voriconazole...

As with all drugs, interactions are important in our patients because our patients have many different pharmaceutical agents on board at the same time. These two drugs are slightly different. Letermovir has more interactions than maribavir, but usually with drugs that we monitor anyway, where we’re used to checking concentration by therapeutic drug monitoring, such as the immunosuppressive agents and voriconazole. Maribavir has few very important interactions, and for that reason, it’s easier to use. On the other hand, because of its indication, which is in resistant and refractory CMV, it is used in fewer patients as well.

 

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

MSD & Takeda.